Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 5/20 | 0.40 |
| ▸ | CTSS | P25774 | 3/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.31 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19578058 | 1.00 | CTSK (0.40) | CTSKCTSSCA1CA2CYP1A2 | |
| SCHEMBL19578077 | 0.86 | CTSK (0.38) | CTSKCTSSCA1CA2CYP1A2 | |
| SCHEMBL19578130 | 0.86 | CTSK (0.42) | CTSKCTSSCA1CA2TGFBR1 | |
| SCHEMBL19334205 | 0.86 | CTSK (0.35) | CTSKCTSSCA1CA2CYP1A2 | |
| SCHEMBL19578131 | 0.85 | CTSK (0.40) | CTSKCTSSCA1CA2CYP1A2 | |
| SCHEMBL8906526 | 0.85 | CTSK (0.41) | CTSKCTSSCA1CA2CYP1A2 | |
| SCHEMBL8906540 | 0.85 | CTSK (0.41) | CTSKCTSSCA1CA2CYP1A2 | |
| SCHEMBL19334207 | 0.82 | SMN1; SMN2 (0.34) | CTSKCTSS | |
| SCHEMBL24851661 | 0.81 | KDM4E (0.39) | CTSKCTSSRIPK1 | |
| SCHEMBL19578425 | 0.80 | CTSK (0.36) | CTSKCTSSCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170320833-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-11-09 | — | — | US | disclosed |
| US-9758487-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170320833-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, PYGL, HCCS | CTSK 789/4885CTSS 864/4885CA1 4434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.